{
    "clinical_study": {
        "@rank": "163144", 
        "acronym": "Activa PC+S", 
        "arm_group": {
            "arm_group_label": "chronic brain recording", 
            "arm_group_type": "Experimental", 
            "description": "This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS).  2)  Study acute and chronic effects of therapeutic DBS on cortical LFPs."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to use an investigational device to record brain activity for\n      12 months following surgical implantation of deep brain stimulation (DBS) systems. The goal\n      of the study is better understanding of brain activity in movement disorders, not to bring\n      new devices to market."
        }, 
        "brief_title": "Chronic Effects of DBS in Parkinson's Disease and Dystonia", 
        "condition": [
            "Parkinson's Disease", 
            "Primary Dystonia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dystonia", 
                "Dystonic Disorders", 
                "Parkinson Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria(both groups):\n\n          -  Ability to give informed consent for the study\n\n          -  Movement disorder symptoms that are sufficiently severe, in spite of best medical\n             therapy, to warrant surgical implantation of deep brain stimulators according to\n             standard clinical criteria\n\n        Inclusion criteria (primary dystonia):\n\n          -  Age 22-75\n\n          -  Primary dystonia that is generalized or segmental, that must affect one or - Stable\n             doses of anti-dystonia medications (such as Artane, Baclofen, or Clonopin) for at\n             least 30 days prior to baseline assessment\n\n          -  For patients with craniofacial involvement, prior treatment with botulinum toxin with\n             failure to adequately control dystonia symptoms.\n\n        Inclusion criteria (PD):\n\n          -  Age 30-75\n\n          -  Bilateral disease (Hoehn and Yahr stage 2 or greater)\n\n          -  Has been treated with levodopa/carbidopa, and with a dopamine agonist, at the maximal\n             tolerated doses as determined by a movement disorders neurologist\n\n          -  Stable doses of antiParkinsonian medications for at least 30 days prior to their\n             baseline assessment\n\n          -  Significant disability in the setting of optimal medical management by a movement\n             disorders neurologist.  Disability may be due to tremor that is unresponsive to\n             medications, or to motor fluctuations\n\n          -  UPDRS-III score off medication between 20 and 60*\n\n          -  Improvement of at least 30% in the baseline UPDRS-III on medication score, compared\n             to the baseline off-medication score.\n\n        Exclusion Criteria (both groups):\n\n          -  Pregnancy or breast feeding\n\n          -  MRI showing cortical atrophy out of proportion to age\n\n          -  MRI showing focal brain lesions that could indicate a non-idiopathic movement\n             disorder,\n\n          -  Major comorbidity increasing the risk of surgery (prior stroke, severe hypertension,\n             severe diabetes, or need for chronic anticoagulation other than aspirin)\n\n          -  Inability to comply with study follow-up visits\n\n          -  Any prior intracranial surgery\n\n          -  Mood depression with a Beck depression inventory score of > 17 on baseline screening\n\n          -  Significant cognitive impairment (MoCA<25).\n\n          -  History of seizures\n\n          -  Immunocompromised\n\n          -  Has an active infection\n\n          -  Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic - Has an\n             implanted electronic  device such as  a neurostimulator, cardiac pacemaker or\n             medication pump."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934296", 
            "org_study_id": "Activa PC+S"
        }, 
        "intervention": {
            "arm_group_label": "chronic brain recording", 
            "description": "Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation", 
            "intervention_name": "Activa PC+S", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "deep brain stimulation", 
            "cortical recording", 
            "neuroprosthesis"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "contact": {
                "email": "sarah.wang@ucsf.edu", 
                "last_name": "Sarah Wang, PhD", 
                "phone": "415-353-7885"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94115"
                }, 
                "name": "UCSF Surgical Movement Disorders Center"
            }, 
            "investigator": {
                "last_name": "Philip A. Starr, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia", 
        "overall_contact": {
            "email": "robin.taylor@ucsf.edu", 
            "last_name": "Robin Taylor, MSN, FNP", 
            "phone": "415-353-1555"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Philip Starr, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cortical synchronization is measured  by the interaction of low frequency rhythms with high frequency activity in the power spectrum of the cortical local field potential.  The measure is called \"phase amplitude coupling\" and is described in detail in our publication, de Hemptinne et al, Exaggerated phase amplitude coupling in the primary motor cortex in Parkinson disease, PNAS 2013, 110:4780-4785", 
            "measure": "Cortical synchronization during chronic therapeutic deep brain stimulation", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934296"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Philip Starr", 
            "investigator_title": "Professor, Neurological Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "Medtronic", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}